Cargando…

Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological treatment approved worldwide. The repositioning of old drugs provides a safe approach for drug development. Vidofludimus, an inhibitor for dihydroorotate dehydrogenase (DHODH)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yanlin, Xu, Shuangshuang, Lu, Yi, Wei, Yijuan, Yao, Benqiang, Guo, Fusheng, Zheng, Xing, Wang, Yumeng, He, Ying, Jin, Lihua, Li, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240069/ https://www.ncbi.nlm.nih.gov/pubmed/32477115 http://dx.doi.org/10.3389/fphar.2020.00590

Ejemplares similares

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
por: Zhou, Mengjiao, et al.
Publicado: (2022)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

PPARγ Transcription Deficiency Exacerbates High-Fat Diet-Induced Adipocyte Hypertrophy and Insulin Resistance in Mice
por: Guo, Fusheng, et al.
Publicado: (2020)

Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling
por: Paraiso, Ines L., et al.
Publicado: (2021)

A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis
por: Carey, Elizabeth J., et al.
Publicado: (2022)

Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
por: Tang, Kaijia, et al.
Publicado: (2022)

Immunomodulatory Therapeutic Strategies in Stroke
por: Malone, Kyle, et al.
Publicado: (2019)

Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning
por: Zhang, Cheng, et al.
Publicado: (2022)

Calculus Bovis Sativus Improves Bile Acid Homeostasis via Farnesoid X Receptor-Mediated Signaling in Rats With Estrogen-Induced Cholestasis
por: Xiang, Dong, et al.
Publicado: (2019)

Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues
por: Kakoti, Bibhuti Bhusan, et al.
Publicado: (2022)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Paeoniflorin alleviates 17α-ethinylestradiol-induced cholestasis via the farnesoid X receptor-mediated bile acid homeostasis signaling pathway in rats
por: Wang, Rulin, et al.
Publicado: (2022)

Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases
por: Festa, Carmen, et al.
Publicado: (2017)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment
por: Menduti, Giovanna, et al.
Publicado: (2020)

Baicalin Protects Against 17α-Ethinylestradiol-Induced Cholestasis via the Sirtuin 1/Hepatic Nuclear Receptor-1α/Farnesoid X Receptor Pathway
por: Yang, Jinyu, et al.
Publicado: (2020)

Immunomodulatory and anti-inflammatory therapeutic potential of gingerols and their nanoformulations
por: Yücel, Çiğdem, et al.
Publicado: (2022)

Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics
por: Chu, Liang-Hui, et al.
Publicado: (2015)

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
por: Muehler, Andreas, et al.
Publicado: (2019)

Overcoming Obstacles to Drug Repositioning in Japan
por: Nishimura, Yuhei, et al.
Publicado: (2017)

Drug repositioning: A bibliometric analysis
por: Sun, Guojun, et al.
Publicado: (2022)

Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer
por: Girisa, Sosmitha, et al.
Publicado: (2021)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Trace Amine-Associated Receptors as Novel Therapeutic Targets for Immunomodulatory Disorders
por: Christian, Sherri L., et al.
Publicado: (2018)

Drug Repositioning in Glioblastoma: A Pathway Perspective
por: Tan, Sze Kiat, et al.
Publicado: (2018)

Enhancing the Promise of Drug Repositioning through Genetics
por: Pritchard, Jayne-Louise E., et al.
Publicado: (2017)

Lead Optimization of Dehydroemetine for Repositioned Use in Malaria
por: Panwar, Priyanka, et al.
Publicado: (2020)

Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
por: Li, Yong, et al.
Publicado: (2020)

Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
por: Xiang, Minqi, et al.
Publicado: (2023)

Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
por: Xiang, Minqi, et al.
Publicado: (2023)

NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment
por: Xia, Ming-Feng, et al.
Publicado: (2019)

Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice
por: Li, Songtao, et al.
Publicado: (2020)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Quantitative High-Throughput Profiling of Environmental Chemicals and Drugs that Modulate Farnesoid X Receptor
por: Hsu, Chia-Wen, et al.
Publicado: (2014)

Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning
por: Merk, Daniel, et al.
Publicado: (2018)

Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning
por: Merk, Daniel, et al.
Publicado: (2018)

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast
por: Schierle, Simone, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n4g5t5g9r0be3r2vvn6fjmb6ma